Overview Science Safety Legal Therapy Checklist Dosage

Therapeutic Research & Applications

As of 2026, no classic psychedelic has full FDA approval for any indication, but the evidence base is strong and policy momentum is accelerating (Trump EO priority vouchers, Phase 3 data).

Leading Indications & Evidence

  • Depression (Psilocybin) — Multiple Phase 2/3 trials (Compass Pathways, Usona, Johns Hopkins). Single or two doses + therapy show large effect sizes; ~50-70% response rates in treatment-resistant populations, with benefits lasting 6–12+ months in follow-ups.
  • PTSD (MDMA) — MAPS/Lykos Phase 3 showed strong results; FDA issued Complete Response Letter in 2024 requesting additional data. 2026 policy push for resubmission/expanded access.
  • Anxiety (LSD) — 2025 JAMA study and ongoing large trials; single dose showing durable relief.
  • Other promising areas — Alcohol use disorder, opioid addiction, end-of-life distress, OCD, eating disorders, post-Lyme symptoms (Johns Hopkins active trials 2026).

How Psychedelic-Assisted Therapy Works

Typically 1–3 dosing sessions in a controlled setting with 2 therapists/guides, preceded by preparation sessions and followed by multiple integration sessions. The drug acts as a catalyst; the therapy and integration do the heavy lifting for lasting change.

2026 Outlook: FDA priority review vouchers issued for psilocybin programs. Possible approvals in 2027–2028 if additional data requirements are met. In the meantime, limited access via clinical trials, Right to Try (U.S.), and special programs in Switzerland, Australia, and select U.S. states.

Trusted resources: Johns Hopkins Center for Psychedelic Research · MAPS · UC Berkeley Center for the Science of Psychedelics · DanceSafe · Zendo Project · Fireside Project

Disclaimer: Cybinly provides this educational content for informational and harm-reduction purposes only. It is not medical, legal, or therapeutic advice. Psychedelic substances remain Schedule I under U.S. federal law and are illegal in most jurisdictions. Laws are rapidly evolving—always verify current regulations with official sources. Consult qualified healthcare professionals before considering any substance. If you or someone you know is in crisis, contact the Fireside Project at (623) 473-7433 or firesideproject.org.

Content reflects research and policy as of mid-2026. Last major update: 2026.